Edition:
United Kingdom

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

28.41USD
17 Nov 2017
Change (% chg)

$0.72 (+2.60%)
Prev Close
$27.69
Open
$28.00
Day's High
$28.68
Day's Low
$27.37
Volume
237,311
Avg. Vol
243,130
52-wk High
$29.21
52-wk Low
$13.51

Latest Key Developments (Source: Significant Developments)

Adamas Pharmaceuticals reports Q3 loss per share $1.04
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results.Q3 loss per share $1.04.Q3 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Adamas Pharmaceuticals Inc - ‍ expects to receive $65 million in funding from healthcare royalty partners in q4 of 2017.Adamas Pharmaceuticals Inc - ‍ believe we will be sufficiently capitalized to launch and commercialize gocovri, among others​.  Full Article

Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Adamas Pharmaceuticals Inc :Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​.  Full Article

Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Adamas Pharmaceuticals Inc :Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​.  Full Article

Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Adamas Pharmaceuticals Inc ::FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI.  Full Article

Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica
Friday, 6 Oct 2017 

Oct 6 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals says ‍on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing.Adamas Pharma - ‍Moehs will supply to adamas amantadine hcl, active pharmaceutical ingredient in Adamas's product Gocovri extended-release capsules​.Adamas Pharmaceuticals Inc - ‍Adamas will provide Moehs with forecasts and purchase orders for quantities of API, and moehs will supply Adamas with API​.Adamas Pharmaceuticals Inc - ‍agreement has a term of 14 years​.  Full Article

Allergan and Adamas enter settlement with Amneal Pharmaceuticals
Wednesday, 31 Aug 2016 

Allergan Plc : Allergan and Adamas announce settlement with Amneal related to namzaric patent litigation . Adamas will grant amneal a license to market generic versions of namzaric beginning on January 1, 2025 . Other terms of settlement were not disclosed . Under certain circumstances, amneal has an option to launch an authorized generic version of namzaric beginning on January 1, 2026 . Settlement provides additional clarity for patent-protected life of namzaric .Alternatively, under certain circumstances, amneal has option to launch authorized generic version of namzaric beginning on January 1, 2026.  Full Article

Adamas reports second quarter 2016 financial results
Thursday, 4 Aug 2016 

Adamas Pharmaceuticals Inc : Adamas reports second quarter 2016 financial results . Q2 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.78.  Full Article

Allergan and Adamas says FDA approved new, expanded label for Namzaric
Tuesday, 19 Jul 2016 

Allergan Plc : In addition to two currently available dosage strengths, two new Namzaric dosage strengths will be available in pharmacies in September. . Allergan and Adamas announce new expanded indication for Namzaric (Memantine and Donepezil Hydrochlorides) extended release for the treatment of moderate to severe Alzheimer's .disease.  Full Article

Adamas Pharmaceuticals reports Q1 loss per share $0.65
Tuesday, 10 May 2016 

Adamas Pharmaceuticals Inc : Adamas reports first quarter 2016 financial results . Q1 loss per share $0.65 .Q1 earnings per share view $-0.76 -- Thomson Reuters I/B/E/S.  Full Article

Adamas Pharmaceuticals announces positive top-line results from its phase 3 EASE LID 3 trial of ADS-5102
Thursday, 28 Apr 2016 

Adamas Pharmaceuticals:Announces positive top-line results from its phase 3 EASE LID 3 Trial of ADS-5102 for treatment of levodopa-induced dyskinesia in patients with parkinson's disease.Says third randomized clinical trial meets primary and key secondary endpoints.Results from this randomized, double-blind, placebo-controlled study showed a statistically significant improvement in LID at 12 weeks for patients who received ADS-5102 versus placebo as assessed by Unified Dyskinesia Rating Scale.  Full Article

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results